Noxopharm (ASX:NOX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Noxopharm (ASX:NOX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Investor Presentation September 2026
Novel oligonucleotides data presented at Options Conference
Noxopharm's Sofra oligonucleotides show promise in reducing inflammation from next-gen mRNA vaccines
Appendix 4E - Preliminary Financial Report
New preclinical data supports immuno-oncology approach
Noxopharm's Sofra technology shows immune activation potential in preclinical cancer studies
New study further validates Noxopharms cancer pipeline
Quarterly Activities/Appendix 4C Cash Flow Report
Noxopharm advances cancer and autoimmune drug programs with Sofra platform; reports cash position and funding plans
Pre-IND meeting request with US FDA
Noxopharm requests pre-IND meeting with US FDA for SOF-SKN autoimmune drug
Sofr platform versatility shown via childbirth MRFF grant
Fast-tracking of cancer program via novel animal model
SOF-SKN manufacturing begins to ensure clinical trial readi
Noxopharm begins SOF-SKN manufacturing ahead of clinical trial for autoimmune skin disease